tiprankstipranks
Lytix Biopharma AS (DE:6BG)
:6BG
Germany Market

Lytix Biopharma AS (6BG) Income Statement

Compare
1 Followers

Lytix Biopharma AS Income Statement

Last quarter (Q4 2022), Lytix Biopharma AS's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Lytix Biopharma AS's net income was $-29.19M. See Lytix Biopharma AS’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ ―$ ―$ ―$ ―
Gross Profit
$ ―$ ―$ ―$ ―
Operating Expenses
$ ―$ ―$ ―$ ―
Depreciation and Amortization
$ 30.00K$ ―$ ―$ ―
EBITDA
$ -55.92M$ -48.05M$ -42.09M$ -32.96M
Operating Income
$ -65.70M$ -48.02M$ -42.37M$ -32.96M
Other Income/Expenses
$ ―$ ―$ ―$ ―
Pretax Income
$ ―$ ―$ ―$ ―
Net Income
$ -56.01M$ -48.05M$ -42.09M$ -32.41M
Per Share Metrics
$ ―$ ―$ ―$ ―
Basic EPS
$ ―$ ―$ ―$ ―
Diluted EPS
$ ―$ ―$ ―$ ―
Weighted Average Shares Outstanding
Weighted Average Shares Outstanding (Diluted)
Currency in USD

Lytix Biopharma AS Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis